Molecular monitoring of patients with chronic myeloid leukemia treated with imatinib mesylate and evaluation of treatment resistance mechanisms: mutation of BCR-ABL and expression of MDR1 and BCRP genes / Acompanhamento molecular de pacientes com leucemia mielóide crônica tratados com mesilato de imatinibe e avaliação dos mecanismos de resistência ao tratamento: mutação do gene BCR-ABL e expressão dos genes MDR1 e BCRP

AUTOR(ES)

Luciana Nardinelli

DATA DE PUBLICAÇÃO

2009

RESUMO

Chronic myeloid leukemia is characterized by t(9;22) translocation. The chimeric gene BCR-ABL encodes a p210BCRABL protein with constitutive tyrosine kinase activity which is directly related to CML pathogenesis. The imatinib mesylate, a tyrosine kinase inhibitor, is the first-choice treatment for patients in chronic phase but some patients show primary resistance or relapse after initial response. The mechanisms of resistance to the imatinib mesylate treatment are BCR-ABL dependent (amplification of BCR-ABL and mutation of kinase domain of BCR-ABL) or independent of BCR-ABL (1-acid glycoprotein and expression of multidrug resistance genes). Objective: The objective of this work was to evaluate the mechanisms of resistance (kinase domain mutation and MDR1 and BCRP genes expression) to imatinib mesylate in pretreatment samples, quantify of BCR-ABL transcript on a monthly follow up plan, and to re-evaluate the mechanisms of resistance in the absence or loss of treatment response. Patients and Methods: We have evaluated 61 pretreatment samples derived from chronic phase CML patients. The number of BCR-ABL transcripts was quantified by RTQ-PCR with taqman probes and MDR1 and BCRP expression were evaluated by RTQ-PCR with Syber Green. Mutations within the BCR-ABL kinase domain were screened by direct sequencing and we also have screened the T315I mutation in pretreatment samples by allele-specific PCR. Results:We detected no mutations in the 61 pretreatment samples. The correlation analysis between the expression of MDR1/BCRP genes and the cytogenetic response at 12 months of treatment revealed no significant statistical difference (p = >0.05). The results of BCR-ABL quantification in the follow up of our cohort indicated that patients who had transcripts <1% by the international scale at 3 months of therapy are more likely to achieve rapid MMR (median of 7 months) than those who had >1% (median of 12 months) (p = 0,03). Conclusions: As expected, the kinase domain mutations of BCR-ABL in pretreatment samples of CML chronic phase patients are not detectable by direct sequencing because of the sensitivity of the assay (10%) and also because these mutations are more common in accelerated phase and blast crisis. About the expression of multidrug resistance genes MDR1 and BCRP, they showed no correlation with secondary resistance to imatinib mesylate. And finally the number of BCR-ABL transcripts at 3 months of treatment can be considered a marker with prognostic value.

ASSUNTO(S)

myelogenous cromossomo filadélfia drug resistance mutation transportadores de cassete de ligação de atp proteínas tirosina quinases reverse transcriptase polymerase chain reaction chronic reação em cadeia da polimerase via transcriptase reversa atp-binding cassette transporters leukemia leucemia mielógena crônica bcr-abl positiva mutação bcr-abl positive philadelphia cromossome protein tyrosine kinases resistência a medicamentos

Documentos Relacionados

• Molecular monitoring of BCR-ABL transcripts in patients with chronic myeloid leukemia treated with imatinib using real-time PCR
• Papel da P190 BCR-ABL como parâmetro de recaída na leucemia mielóide crônica
• Alterações cromossômicas e freqüência do rearranjo gênico BCR/ABL ao diagnóstico, tratamento com mesilato de imatinibe e após transplante de medula óssea em leucemia mielóide crônica
• A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
• Expressão do rearranjo gênico BCR-ABL com ponto de quebra na região menor do gene BCR em um paciente com leucemia mielóide crônica